Home > Insider Trading > Filing (0001209191-21-030625)

Filing Details

Accession Number:: 0001209191-21-030625
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-06 13:00:00
Reporting Period:: 2021-05-04

Accepted Time:: 2021-05-06 16:19:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785530	Werewolf Therapeutics Inc.	HOWL	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1719960	Mpm Oncology Innovations Fund Lp	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1857903	Mpm Oncology Innovations Fund Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-04	4,477,742	$0.00	4,939,150	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-05-04	1,488,033	$0.00	6,427,183	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-05-04	245,000	$16.00	6,672,183	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-05-04	38,817,998	$0.00	4,477,742	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-05-04	12,899,925	$0.00	1,488,033	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF.
MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology.
The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology.
No securities held by the Reporting Persons.
The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology.